Immatics $58m Series E To Fund T-Cell Receptor-Based IO Therapies
The clinical-stage biopharma's latest financing of $58m will be used to progress its immunotherapy pipeline and proprietary platform, bringing its funding to date to just over $230m.
You may also be interested in...
German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.